NEOIMMUNETECH
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics.
NEOIMMUNETECH
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.neoimmunetech.com
Total Employee:
1+
Status:
Active
Contact:
+82-31-709-5858
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Font Awesome Apache ReCAPTCHA GoDaddy DNS ReCAPTCHA V2
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-25 | NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer |
Official Site Inspections
http://www.neoimmunetech.com Semrush global rank: 7.05 M Semrush visits lastest month: 617
- Host name: ec2-43-200-231-7.ap-northeast-2.compute.amazonaws.com
- IP address: 43.200.231.7
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "NeoImmuneTech"
NeoImmuneTech
Founded in 2014 in Rockville, Maryland, NeoImmuneTech is a biotechnology company focused on developing T cell-based therapeutics, particularly NT-I7 (efineptakin alfa), to treat cancer and infectious diseases. NT-I7, the โฆSee details»
NeoImmuneTech - Crunchbase Company Profile & Funding
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious โฆSee details»
About Us - neoimmunetech.com
We uphold transparency and honesty based on our strong belief in technology. Our philosophy of integrity leads to cost reduction and investment creation through transparent financial โฆSee details»
ํ์ฌ์๊ฐ - neoimmunetech.com
Neoimmunetech, ๋ค์ค์ด๋ฎจํ , ํญ์์ฑ ์ธํฌ ์ฆ์, ์ข ์ ๋ด ๋ฆผํ๊ตฌ ์ฆ๊ฐ, T์ธํฌ ์์ฉ์ฒด์ ํด๋ก ์ฑ ์ฆ๊ฐ, T์ธํฌ์ ์ค๊ธฐ์ธํฌ ํน์ฑ์ ์ ๋, ํ ํญ์ modality์์ ๋๋ฐ์์น ํจ๋ฅSee details»
NeoImmuneTech - LinkedIn
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious โฆSee details»
NeoImmuneTech Company Profile | Management and Employees โฆ
Find contact information for NeoImmuneTech. Learn about their Research & Development, Business Services market share, competitors, and NeoImmuneTech's email format.See details»
NeoImmuneTech, Inc.
NeoImmuneTech is actively developing NT-I7 in ARS through partnerships with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health โฆSee details»
Company profile: NeoImmuneTech - pharmaphorum
Jan 29, 2014 About NeoImmuneTech, Inc. Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to โฆSee details»
Neoimmunetech, Inc. Company Profile | Rockville, MD
Find company research, competitor information, contact details & financial data for Neoimmunetech, Inc. of Rockville, MD. Get the latest business insights from Dun & Bradstreet.See details»
NeoImmuneTech Overview | SignalHire Company Profile
The NeoImmuneTech annual revenue is estimated at < 1M. Total funding of the company - $103.4M. To connect with NeoImmuneTech employee register on SignalHire. Organization โฆSee details»
NeoImmuneTech - VentureRadar
Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno โฆSee details»
NeoImmuneTech 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for NeoImmuneTech. Use the PitchBook Platform to explore the full profile.See details»
NeoImmuneTech - businessabc.net
Feb 25, 2025 NeoImmuneTech was founded in California in 2012 by medical researchers from the University of California, San Francisco and Stanford University. It was funded by a โฆSee details»
NeoImmuneTech - Overview, News & Similar companies
View NeoImmuneTech (www.neoimmunetech.com) location in Maryland, United States , revenue, industry and description. Find related and similar companies as well as employees by title and โฆSee details»
NeoImmuneTech - Craft
NeoImmuneTech (NIT) is a biotech company developing immunotherapeutics for cancer and infectious diseases. It develops NT-I7, a T-cell amplifier that enhances immune functions. The โฆSee details»
NeoImmuneTech - Work in biotech
NeoImmuneTech is a clinical-stage biopharmaceutical company creating innovative T cell therapies that harness the immune system to target and destroy cancer cells. They are โฆSee details»
NeoImmuneTech begins trial of primates for acute radiation โฆ
Dec 24, 2024 NeoImmuneTech has signed an agreement with U.S. contract research organization Charles River Laboratories International (CRL) to conduct a study of primates for โฆSee details»
Development Status - neoimmunetech.com
Continuous efforts for foundational research and proof of concept NeoImmuneTech is currently conducting combination clinical trials of NT-I7 with various therapeutics, including immune โฆSee details»
NeoImmuneTech Welcomes a New President for its Development โฆ
Jan 15, 2024 His primary focus will be on accelerating the clinical development of NT-I7, NeoImmuneTech's long-acting human IL-7, and strategizing the regulatory path for its โฆSee details»
Autoimmune Disease Treatment and Management - National โฆ
NIAID-supported research has contributed to great increases in the number and efficacy of autoimmune disease treatment approaches available. Even so, unmet needs remain. These โฆSee details»